In community and public health nursing, the target of care is the community, thus the community is the client receiving the care

/in /by

 Post your initial response to the topic below.

In community and public health nursing, the target of care is the community, thus the community is the client receiving the care. The role of the nurse is to evaluate health concerns and develop an aggregate plan of care to address those concerns. Aggregates or target populations in the community may include child care centers, cities, counties, senior centers, homeless shelters, minority communities, faith-based organizations, work sites, schools, or other populations.

Identify and discuss a few targeted populations in your community that are of interest to you.

Provide your rationale  for the selections identified.

I want the discussion to be base on a community hospital on telemetry/cardiovascular floor

The post In community and public health nursing, the target of care is the community, thus the community is the client receiving the care appeared first on Infinite Essays.

Self-Directed Learning Plan (SDLP)

/in /by

Self-Directed Learning Plan (SDLP)

Purpose:

It’s important to develop your professional goals and how you achieve them in this course and your chosen program.

Directions:

To prepare your SDLP, complete the steps outlined below.

After exploring the course description, course outcomes, and unit themes and outcomes, complete your SDLP for your professional objectives.

What did you expect to learn in this course and what do you expect to learn in your program that will help you achieve your academic and professional goals? You are encouraged to reflect earnestly about how the course content and experience might serve your goals, as well as about what you might proactively do in throughout your program to develop in your target areas.

If you have determined there are additional areas from which you would benefit, or areas you would like to replace, this is a good time to do so. Remember, this is your learning plan, so design it to help you achieve your unique goals.

  1. Identify your anticipated nursing role.
  2. List your professional goals (3–5 years from now).
  3. Identify the Knowledge, Skills, and Accomplishments needed for the advanced nursing role that you have identified above. A minimum of three items should be listed for each of the Knowledge, Skills, and Accomplishments.
  4. Discuss at least three Strengths to Leverage. Complete steps 1, 2, and 3 of the template for Strengths to Leverage.
  5. Discuss at least one Area to Develop. Complete steps 1, 2, and 3 of the template for Areas to Develop.
  6. Write a reflection that discusses what you learned in this course and expect to learn in your program that will help you achieve your academic and professional goals. Provide an evaluation of how your SDLP can provide for lifelong learning. The reflection should be a minimum of 300 words.

You must submit the Unit 10 SDLP Assignment using the SDLP Template. You should not submit a written paper for the Unit 10 SDLP Assignment. If you have references to support your SDLP then you should add a heading References at the end of the SDLP Template and add the references in APA format. You do not need to have a title page for this assignment.

This Assignment will be graded based on evidence of thoughtful development of your SDLP.

To view the Grading Rubric for this Assignment, please visit the Grading Rubrics section of the Course Resources.

Assignment Requirements:

Before finalizing your work, you should:

  • be sure to read the Assignment description carefully (as displayed above);
  • consult the Grading Rubric (under the Course Resources) to make sure you have included everything necessary; and
  • utilize spelling and grammar check to minimize errors.

Your writing Assignment should:

  • follow the conventions of Standard English (correct grammar, punctuation, etc.);
  • be well ordered, logical, and unified, as well as original and insightful;
  • display superior content, organization, style, and mechanics; and
  • use APA 6th Edition format.
  • Please see the Writing Center located in the student portal for assistance with writing, APA, and online communication.

The post Self-Directed Learning Plan (SDLP) appeared first on Infinite Essays.

Choose one of this week’s complementary therapies, such as Ayurveda, Sufism, or Chinese Medicine.

/in /by

Complementary Therapies

Choose one of this week’s complementary therapies, such as Ayurveda, Sufism, or Chinese Medicine.

· What is your opinion of the value of this therapy?

· What do you base your opinion on?

· Would you recommend this therapy? Why or why not? How would you discuss this method if asked by a patient?

· Review two of the postings by a peer (on different complementary therapies) and compare and contrast the evidence and usage of that therapy with the therapy you chose.

· Support your paper with 3 nursing articles not older than 5 yrs. Your essay covered all questions

The post Choose one of this week’s complementary therapies, such as Ayurveda, Sufism, or Chinese Medicine. appeared first on Infinite Essays.

Decision Tree for Neurological and Musculoskeletal Disorders (Alzheimer’s disease)

/in /by

Decision Tree for Neurological and Musculoskeletal Disorders (Alzheimer’s disease)

Name

Course

Instructor

 

Summary of the patient case study 

Mr. Akkad is a 76 year old Iranian male who was brought to the clinic because his eldest son has noted strange behavior, but after laboratory and diagnostic tests he was considered normal. The son is concerned because of his father’s strange thoughts and disinhibited behaviors. After administering Mini-Mental State Exam (MMSE), Mr. Akkad scored 18 out of 30 and there were primary deficits in different areas.

The chosen decisions are:  Begin Exelon (rivastigmine) 1.5 mg orally BID with an increase to 3 mg orally BID in 2 weeks, Increase Exelon to 4.5 mg orally B, and increase Exelon to 6 mg orally BID.  In decision point one, Begin Exelon (rivastigmine) 1.5 mg orally BID with an increase to 3 mg orally BID in 2 weeks, the client returns to clinic in four weeks, but the son reports that the father is not better and is disinterested in religious activities or services. In decision point two, the client returns to clinic in four weeks and the son reported the father had started tolerating the medication, but was no better, while he had started attending religious services. Increasing Exelon to 4.5 and then 6.0 mg orally is beneficial as there are no side effects, but the medications do not reverse the degenerative process.

Decisions provided were supported by the evidence-based literature. 

The initial treatment is Begin Exelon (rivastigmine) 1.5 mg orally BID with an increase to 3 mg orally BID in 2 weeks and when well tolerated dosage is increased unless there are adverse effects. Exelon (rivastigmine) is a type of cholinesterase inhibitors (acetylcholinesterase inhibitors) used to treat mild to moderate Alzheimer’s disease and its efficacy is related to the dosage. The safety and efficacy of the medication has been evaluated in various trials (Birks & Evans, 2015).  Researchers mostly look into changes in activities of daily living and behavioral symptoms and effectiveness f different medications to teat Alzheimer’s to determine what is best suited for patients.

When Exelon was increased to 4.5 mg this was based on the observation that the treatment is increased to the recommended optimal dose when well tolerated after 4 weeks. There is also no switch of the medications within the same class without good reason. In a review of research there was no difference in cognitive function measured using various neuropsychological assessment tools such as the Alzheimer’s Disease Assessment Scale-Cognitive Subscale (ADAS-Cog scale ) when Exelon (4.6 mg/day) and placebo were used for 24 weeks (Birks & Evans, 2015). The recommended Exelon dosage is 6-12 mg/ day, but more dosage may be beneficial.

What I hoped to achieve with the decisions 

In decision point one Exelon was provided 1.5 mg orally and increased to 3 mg orally in 2 weeks, which is consistent with recommendations, and was aimed at improving daily functioning. Acetylcholinesterase inhibitors such as Exelon inhibit the degradation of the acetylcholine and may boost cholinergic functioning and cholinergic neurotransmission and in patients with Alzheimer’s disease (Deardorff, Feen & Grossberg, 2015). Mini-Mental State Examination (MMSE) indicates cognitive functioning and without improvement the second decision point was increasing the dosage.

As expected, Akkad tolerated the medication when the dose was now 4.5 mg and since there was no interruption of treatment there was no restarting the treatment with the same dose. Dose increase ought to occur only after 4 week or more and the client returned after four weeks, and expectedly the father was attending religious services. In decision point three, I hope d to improve cognitive functioning and daily activities. Deardorff, Feen & Grossberg (2015) report on a on a clinical trial that had shown significant improvements on the ADAS-Cog and MMSE, when using Exelon 6-12 mg/day for patients with Alzheimer’s. As there were no side effects in decision point two the dose was increased to reach the therapeutic dose of the medication

Difference between expectations and the results 

In decision point one, there was expectation that Exelon (rivastigmine) 1.5 mg orally BID and increase to 3 mg would have a positive effect, but there was no change. The MMSE score did not change, but the recommendations highlight the need to give the medications gradually to avoid adverse effects. This was considered in decision point two to avoid adverse events and side effects when there is rapid increase in the dose. The Exelon 6 mg -12 mg orally is most effective to improve outcomes for cognitive function when dose is increased gradually to these levels (Birks & Evans, 2015).  According to Deardorff, Feen & Grossberg (2015) there are significant improvement in patients with Alzheimer’s disease when the dosage is gradual rather than starting with a high dosage.

In decision point two the chosen to increase Exelon to 6 mg orally within the four weeks was not chosen as there are likely adverse effects such as vomiting and losing appetite and this is mostly when there was rapid uptitration of Exelon. According to Khoury, Rajamanickam & Grossberg (2018), there is higher risk of incidence of gastrointestinal side effect when using

Exelon when compared to Donepezil and galantamine the other cholinesterase inhibitors (ChEIs) that are the first-line treatment for Alzheimer’s. In decision point three, the goal of increasing Exelon to 6 mg orally BID improve outcomes and daily functioning as expected.

 

The post Decision Tree for Neurological and Musculoskeletal Disorders (Alzheimer’s disease) appeared first on Infinite Essays.